Literature DB >> 22388106

Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection.

Conor P Delaney1, Christopher Craver, Melinda M Gibbons, Amy W Rachfal, Christine J VandePol, Suzanne F Cook, Sara A Poston, Michael Calloway, Lee Techner.   

Abstract

OBJECTIVE: To evaluate in-hospital clinical outcomes after open and laparoscopic bowel resection (BR) with or without alvimopan treatment. <br> BACKGROUND: Delayed return of gastrointestinal function after BR may be associated with greater postoperative morbidity and increased hospital length of stay (LOS). In clinical trials, alvimopan--a peripherally acting μ-opioid receptor antagonist--accelerated gastrointestinal recovery after open BR. <br> METHODS: A retrospective matched-cohort study (NCT01150760) was conducted using a national inpatient database. Each alvimopan patient was exact matched (surgical procedure, surgeon specialty) and propensity score matched (baseline characteristics) to a nonalvimopan BR patient. Outcomes included gastrointestinal and other morbidity (cardiovascular, pulmonary, infection, cerebrovascular, thromboembolic); mortality; readmission rate; and intensive care unit (ICU) stay (intent-to-treat [ITT] population). Postoperative LOS and estimated cost were also compared (modified ITT population). <br> RESULTS: Each cohort included 3525 ITT patients with similar baseline characteristics. Gastrointestinal (29.8% vs 35.7%) and other morbidity (cardiovascular [19.4% vs 24.0%], pulmonary [7.3% vs 10.5%], infectious [9.6% vs 11.8%], thromboembolic [1.2% vs 2.1%]), mortality (0.4% vs 1.0%), and mean ICU stay (0.3 vs 0.6 days) were lower in the alvimopan group (P ≤ 0.003 for each). Postoperative LOS and estimated direct cost were lower for all alvimopan patients and after laparoscopic and open BR (LOS: -1.1, -0.8, and -1.8 days respectively; cost: -$2345, -$1382, and -$3218, respectively; P ≤ 0.0008 for each). <br> CONCLUSIONS: On average, alvimopan-treated patients had a lower incidence of mortality and most incidents of morbidities. Length of stay, ICU use, and estimated cost were also lower with comparable readmissions. These results in patients outside the clinical trial setting include laparoscopic colectomy and demonstrate a potential association between acceleration of gastrointestinal recovery and improved early postoperative outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388106     DOI: 10.1097/SLA.0b013e31824a36cc

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Turning up the heat on surgical cold.

Authors:  William K Schmidt
Journal:  Temperature (Austin)       Date:  2017-04-14

2.  Alvimopan in the setting of colorectal resection with an ostomy: To use or not to use?

Authors:  Yuxiang Wen; Murad A Jabir; Michael Keating; Alison R Althans; Justin T Brady; Bradley J Champagne; Conor P Delaney; Scott R Steele
Journal:  Surg Endosc       Date:  2016-12-07       Impact factor: 4.584

Review 3.  Reducing the burden of postoperative ileus: evaluating and implementing an evidence-based strategy.

Authors:  Jeffrey F Barletta; Anthony J Senagore
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

4.  Alvimopan, Regardless of Ileus Risk, Significantly Impacts Ileus, Length of Stay, and Readmission After Intestinal Surgery.

Authors:  Ahmed M Al-Mazrou; Onur Baser; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2018-07-09       Impact factor: 3.452

5.  Alvimopan Use, Outcomes, and Costs: A Report from the Surgical Care and Outcomes Assessment Program Comparative Effectiveness Research Translation Network Collaborative.

Authors:  Anne P Ehlers; Vlad V Simianu; Amir L Bastawrous; Richard P Billingham; Giana H Davidson; Alessandro Fichera; Michael G Florence; Raman Menon; Richard C Thirlby; David R Flum; Farhood Farjah
Journal:  J Am Coll Surg       Date:  2016-02-05       Impact factor: 6.113

6.  Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients.

Authors:  Janice Jang; Benjamin Kwok; Hua Zhong; Yuhe Xia; Alexis Grucela; Mitchell Bernstein; Feza Remzi; David Hudesman; Jingjing Chen; Jordan Axelrad; Shannon Chang
Journal:  Dig Dis Sci       Date:  2019-09-14       Impact factor: 3.199

7.  Application of and Clinical Research on Enhanced Recovery After Surgery in Perioperative Care of Patients With Supratentorial Tumors.

Authors:  Jingmi Wu; Weina Zhang; Jie Chen; Hui Fei; Hong Zhu; Haofen Xie
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 5.738

Review 8.  Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Authors:  Marta Sobczak; Maciej Sałaga; Martin A Storr; Jakub Fichna
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.